Katarzyna Pruszczyk

Dr. Katarzyna Pruszczyk

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Genes
Verified
Journal Article
Open access
PDF file
ADAnna Deregowska
Anna Deregowska
MPMonika Pepek
Monika Pepek
KPKatarzyna Pruszczyk
Katarzyna Pruszczyk
MMMarcin Machnicki
Marcin Machnicki
Maciej WnukMaciej Wnuk
Maciej Wnuk
TSTomasz Stoklosa
Tomasz Stoklosa
Telomeres are specialized nucleoprotein complexes, localized at the physical ends of chromosomes, that contribute to the maintenance of genome stability. One of the features of chronic myeloid leukemia (CML) cells is a reduction in telomere length which may result in increased genomic instability and progression of the disease. Aberrant telomere maintenance in CML is not fully understood and other mechanisms such as the alternative lengthening of telomeres (ALT) are involved. In this work, we employed five BCR-ABL1-positive cell lines, namely K562, KU-812, LAMA-84, MEG-A2, and MOLM-1, commonly used in the laboratories to study the link between mutation, copy number, and expression of telomere maintenance genes with the expression, copy number, and activity of BCR-ABL1. Our results demonstrated that the copy number and expression of BCR-ABL1 are crucial for telomere lengthening. We observed a correlation between BCR-ABL1 expression and telomere length as well as shelterins upregulation. Next-generation sequencing revealed pathogenic variants and copy number alterations in major tumor suppressors, such as TP53 and CDKN2A, but not in telomere-associated genes. Taken together, we showed that BCR-ABL1 kinase expression and activity play a crucial role in the maintenance of telomeres in CML cell lines. Our results may help to validate and properly interpret results obtained by many laboratories employing these in vitro models of CML.

5 June 2019 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
KPKatarzyna Pruszczyk
Katarzyna Pruszczyk
KBKrzysztof Bartnik
Krzysztof Bartnik
KBKrzysztof Bogusz
Krzysztof Bogusz
RFRoiya Farhan
Roiya Farhan
DCDominika Cwil
Dominika Cwil
ESEmilian Snarski
Emilian Snarski

6 September 2018 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
KBKrzysztof Bartnik
Krzysztof Bartnik
KPKatarzyna Pruszczyk
Katarzyna Pruszczyk
KSKamila Skwierawska
Kamila Skwierawska
MKMałgorzata Król
Małgorzata Król
MPMilena Płachta
Milena Płachta
ESEmilian Snarski
Emilian Snarski

30 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AJAleksandra Justyna
Aleksandra Justyna
ODOlga Dzikowska-Diduch
Olga Dzikowska-Diduch
SPSzymon Pacho
Szymon Pacho
MCMichał Ciurzyński
Michał Ciurzyński
MSMarta Skowrońska
Marta Skowrońska
PPPiotr Pruszczyk
Piotr Pruszczyk
Background: Decreased hemoglobin concentration was reported to predict long term prognosis in patients various cardiovascular diseases including congestive heart failure and coronary artery disease. We hypothesized that hemoglobin levels may be useful for post discharge prognostication after the first episode of acute pulmonary embolism. Therefore, the aim of the current study was to evaluate a potential prognostic value of a decreased hemoglobin levels measured at admission due to the first episode of acute PE for post discharge all cause mortality during at least 2 years follow up. Methods: This was a prospective, single-center, follow-up, observational, cohort study of consecutive survivors of the first PE episode. Patients were managed according to ESC current guidelines. After the discharge, all PE survivors were followed for at least 24 months in our outpatient clinic. Results: During 2 years follow-up from the group of 402 consecutive PE survivors 29 (7.2%) patients died. Non-survivors were older than survivors 81 years (40–93) vs. 63 years (18–97) p < 0.001 presented higher sPESI 2 (0–4) vs. 1 (0–5), p < 0.001 driven by a higher frequency of neoplasms (37.9% vs. 16.6%, p < 0.001); and had lower hemoglobin (Hb) level at admission 11.7 g/dL (6–14.8) vs. 13.1 g/dL (3.1–19.3), p < 0.001. Multivariable analysis showed that only Hb and age significantly predicted all cause post-discharge mortality. ROC analysis for all cause mortality showed AUC for hemoglobin 0.688 (95% CI 0.782–0.594), p < 0.001; and for age 0.735 (95% CI 0.651–0.819) p < 0.001. A group of 59 subjects with hemoglobin < 10.5 g/dL showed mortality rate of 16.9% (OR for mortality 4.19 (95% CI 1.82–9.65), p-value < 0.00, while among 79 patients with Hb > 14.3 g/dL only one death was detected. Interestingly, patients in age > 64 years hemoglobin levels < 13.2 g/dL compared to patients in the same age but with >13.2 g/dL showed OR 3.6 with 95% CI 1.3–10.1 p = 0.012 for death after the discharge. Conclusions: Lower haemoglobin measured in the acute phase especially in patients in age above 64 years showed significant impact on the prognosis and clinical outcomes in PE survivors.

1 December 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
KPKatarzyna Pruszczyk
Katarzyna Pruszczyk
MPMilena Płachta
Milena Płachta
EUElżbieta Urbanowska
Elżbieta Urbanowska
MKMałgorzata Król
Małgorzata Król
MKMaria Król
Maria Król
ESEmilian Snarski
Emilian Snarski